0OT trade ideas
OCUL - long - upcoming catalystOcular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
This is not a financial advice!
Recent block buy
Upcoming catalyst
Keep an eye on 5.0 level - needs to get broken for a further upmove.
SL under 3.7
TP approx. 9.0 maybe even to 12.00 area.
Most info on the chart.
Trade carefully!
OCUL LongAnother chance for a clean swing at nearly 2 r/r. Looks like a complex pullback, but pullback it is.
$OCUL Ocular Therapeutix Inc Long term Target PT 29 and higherNASDAQ:OCUL Ocular Therapeutix Inc
Long term Target PT 29 and higher
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
OCUL is looking attractive OCUL is shaping up for a good risk reward set up.
$3.60 before resistance and well within major downtrend line.
Starter position below $3.
Will add if it falls closer to $2.50, where it has lots of support.
Profit opportunity is 10 - 20%
OCUL good swing opportunity available if price retestsOCUL created a pro gap and if price comes to retest , planning to take a long swing poistion to fill the sep 22 gap .
oculari have no idea what this is but the 50ema is about to coincide with the midpoint of bb, and td89 just happened, so i bet it bounces
$OCUL PT 40 and higherCup and Handle formation
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
OCUL. More Chaos than Order.This is a great example of a chart that makes me realize there is much more to learn. I know there is a way to classify almost every market, but for the life of me I don't know this one.
That makes me all the more motivated to monitor it, however.
$OCUL Buying it againThe stock is showing a good wave structure
It has a bit of spiky pullback during its wave 4
The candles have broken the highs and failed a few times
Apart from the above, it's looking really good for another push-up
I've lost 0.5R on it once. If this second and final attempt goes well
then I will recover the previous investment and plus 1R on top.
So here we go again
Buy Price $21.50
Target 1 $ 23.50 (Close Half and Move SL to BE)
Target 2 $29.50
OCUL is looking bullish and about to break outNASDAQ:OCUL is about to break out. Long the break out at 20, the anticipated price action is shown on the chart, stop at 17$.
Hit the like button and follow if you find this useful :)
This is only my own view and not financial advice, do your own analysis before buying or selling
Happy Trading!
$OCUL setting up to breakout above downward channel resistance.Wait for the 4hr candle to close above $19 for confirmation, has been rejected by this downward channel multiple times.
BUY Setup - OCUL Breakout Trade in to wave 5Here we have another stock with a lovely wave 3 up
a nice not too complex wave 4 down
price has squeezed into a tight box allowing us to take a tight 3 dollar stop
Entry Price $21
Stop $18 (or maybe even 18.50)
Target 1: $23.50
Target 2: $26
Fingers Crossed!!!
Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
$OCULEntry price : 19.54
Fundamentals :
- Sector: Medical
- EPS % Chg (Last Qtr): 48%
- EPS % Chg (Previous Qtr): -12%
- 3 Year EPS Growth Rate: 0%
- EPS Est % Chg (Current Yr): 0%
- Sales % Chg (Last Qtr): 608%
- Sales % Chg (Previous Qtr): 142%
- 3-Year Sales Growth Rate: 75%
- Annual Pre -Tax Margin: -2043.3%
unusual options volume$OCUL
someone bought a bunch of Jan 2021 expiry 23C's early this afternoon. This name isn't a big option trader with average daily option volume barely over 400 contracts.
Volume today on the 23C strike is currently 1058 against only 16 contract OI. They paid around 1.60 to 1.80.
$OCUL can rise in the next daysContextual immersion trading strategy idea.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology.
The share price rose after the company announced topline phase 1 clinical trial results of OTX-CSI.
The demand for shares of the company still looks higher than the supply.
These and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $11,22;
stop-loss — $10,00.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
OCUL Ichimoku Clouds entry LONGIf we close above cloud today, this ticker will hit all 4 entry conditions. OCUL historically has a 64.7% win rate and 1.62% average gain using this strategy.
Earnings Play-OCULOCUL
OCUL has a pattern of descending triangles over the past 4-months (July-November 2019). The company launched its second commercial product Dextenza in the 2nd quarter where it gave away free samples. Its other product 'ReSure Sealent' has posted weak sales numbers ($472K in 1Q19 and ~600K in 2Q19). Dextenza is priced at $850 and is essentially an alternative to prescription eye-drops indicated for the treatment of inflammation and pain post-ocular surgery. Analysts are expecting a decline in EPS compared to the same period in 2018. I think the high price tag (even with J-code) for Dextenza and the strategy of giving away free product will translate to weak sales figures and will send the share price lower. This has been the short-term reaction after 1Q19 and 2Q19 earnings. Although the share price recovered to a high of ~$5.32 this summer it's since decayed and is trading down -17% YTD. Short interest is at 15% which supports a bearish outlook. I think it will reach a ~$3.83 ahead of earnings and then subsequently decline to ~$2.46.
OCUL - A quarter of big progress should start to garner interest
OCUL has had many difficulties over the past number of years, but finally, after shaking up management, getting over manufacturing and regulatory hurdles, and now receiving a broadened label and clarity on reimbursement the stock looks like a screaming buy. While it is always tricky to invest when a biopharma company is going through a product launch, it would seem that the expectations at this point far underestimate the likely potential long-term adoption of DEXTENZA with expanded label and reimbursement codes in place. There is no doubt that DEXTENZA represents a step function improvement in an archaic and highly complex manual eye-drop regime, it should only be a matter of execution on the company's part to fully penetrate what should be a very sizable opportunity ($500 Million - $1 Billion plus) in post surgical inflammation and pain. As the market warms up to this reality, current valuation should expand significantly.
Neutral ERBearish head and shoulders setup. Most likely no sales. I will look to add after retracement. Potential AB=BC harmonic correction.
Disclosure: I do not own shares of OCUL. This is not a note to buy or sell. please do your hw before investing.
